文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

骨髓增生异常综合征的替代供者移植:单倍体与相合无关供者比较

Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors.
PubMed 文献 · Blood Adv · 2021-01-01

基于CIBMTR数据库比较603例MDS患者接受单倍体相合亲缘供者(n=176)与HLA相合无关供者(n=427)移植的结局,所有患者均采用减低强度预处理。单倍体组复发率更高(2年48% vs 33%)且无病生存率更低(2年29% vs 36%),但两组总生存率无差异(2年46% vs 44%),因单倍体组慢性GVHD相关死亡更低。

要点

  • 单倍体供者移植复发率更高(2年48% vs 33%),无病生存率更低(2年29% vs 36%)
  • 两组总生存无差异(2年46% vs 44%),因单倍体组慢性GVHD相关死亡更低(2年6% vs 21%)
  • 单倍体供者移植急性2-4级GVHD和慢性GVHD发生率均更低

核心结论

  • 单倍体亲缘供者移植复发率更高且无病生存率更低,但总生存率与HLA相合无关供者移植无差异。

研究设计与样本

  • 回顾性队列研究,基于CIBMTR数据库,纳入2012至2017年603例MDS患者,单倍体组176例,相合无关供者组427例,均采用减低强度预处理。

主要发现

  • 2年慢性GVHD相关死亡概率单倍体组6% vs 相合无关供者组21%。

关键数值与推荐

  • 单倍体移植预处理以TBI+环磷酰胺+氟达拉滨为主,GVHD预防统一为移植后环磷酰胺+钙调磷酸酶抑制剂+霉酚酸酯。
  • 相合无关供者移植预处理以氟达拉滨+白消安或美法仑为主,GVHD预防为钙调磷酸酶抑制剂+霉酚酸酯或甲氨蝶呤。

临床怎么用

  • 两种供者类型均可扩大MDS患者移植可及性;单倍体移植需优化复发控制策略,无关供者移植需强化GVHD预防。

局限性

  • 为回顾性研究,预处理方案和GVHD预防在不同供者类型间存在差异,可能影响结局比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We compared outcomes in 603 patients with myelodysplastic syndrome (MDS) after HLA-haploidentical relative (n = 176) and HLA-matched unrelated (n = 427) donor hematopoietic cell transplantation (HCT) from 2012 to 2017, using the Center for International Blood and Marrow Transplant Research database. All transplantations used reduced-intensity conditioning regimens. Total-body irradiation plus cyclophosphamide and fludarabine was the predominant regimen for HLA-haploidentical relative donor HCT, and graft-versus-host disease (GVHD) prophylaxis was uniformly posttransplantation cyclophosphamide, calcineurin inhibitor, and mycophenolate. Fludarabine with busulfan or melphalan was the predominant regimen for HLA-matched unrelated donor HCT, and GVHD prophylaxis was calcineurin inhibitor with mycophenolate or methotrexate. Results of multivariate analysis revealed higher relapse (hazard ratio [HR], 1.56; P = .0055; 2-year relapse rate, 48% vs 33%) and lower disease-free survival (DFS) rates after HLA-haploidentical relative donor HCT (HR, 1.29; P = .042; 2-year DFS, 29% vs 36%). However, overall survival (OS) rates did not differ between donor type (HR, 0.94; P = .65; 2-year OS, 46% for HLA-haploidentical and 44% for HLA-matched unrelated donor HCT) because of mortality associated with chronic GVHD. Acute grade 2 to 4 GVHD (HR, 0.44; P < .0001) and chronic GVHD (HR, 0.36; P < .0001) were lower after HLA-haploidentical relative donor HCT. By 2 years, probability of death resulting from chronic GVHD was lower after HLA-haploidentical relative compared with HLA-matched unrelated donor HCT (6% vs 21%), negating any potential survival advantage from better relapse control. Both donor types extend access to transplantation for patients with MDS; strategies for better relapse control are desirable for HLA-haploidentical relative donor HCT, and effective GVHD prophylaxis regimens are needed for unrelated donor HCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Grunwald MR, Zhang MJ, Elmariah H, et al. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Adv. 2021. PMID: 33576783. doi:10.1182/bloodadvances.2020003654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。